Mometasona Ratiopharm (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside nasal mucosal cells. The drug‑receptor complex then alters gene transcription, suppressing the production of inflammatory cytokines and mediators while promoting anti‑inflammatory proteins. This results in decreased vascular permeability, edema, and mucus production in the nasal lining.

The exact dosing regimen for Mometasona Ratiopharm is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Typical adult dosing may involve one or two sprays per nostril once daily, but the prescriber will provide specific instructions.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometasona Ratiopharm (mometasone furoate) is a high‑potency intranasal corticosteroid with a low systemic bioavailability, similar to fluticasone propionate. Compared with some older agents, it often provides effective symptom control with once‑daily dosing and a favorable safety profile, though individual response may vary.

Store the nasal spray at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children. Do not freeze the product.

Before use, gently blow the nose to clear the nostrils. Tilt the head slightly forward, insert the spray tip into one nostril, and close the opposite nostril with a finger. Press the pump while breathing in gently through the nose, then repeat in the other nostril if prescribed. Avoid sniffing hard after spraying.

Serious risks, though rare, include adrenal suppression with prolonged high‑dose use, ocular complications such as cataracts or glaucoma, opportunistic fungal infections of the nasal passages, severe allergic reactions (anaphylaxis), and nasal septum perforation. Patients should report any unusual symptoms to their healthcare provider promptly.

Mometasona Ratiopharm should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery without physician guidance, or those for whom systemic corticosteroid exposure poses a significant risk.